Manufacturers lament DH’s decision to raise sales tax on branded medicines
This article originally appeared in our sister publication Pink Sheet
The DH has confirmed plans to raise payments made by drug companies in the statutory scheme for branded medicines to 24.4% for 2023, despite clear warnings from the pharmaceutical industry against the hike.
